Hematologic Oncology Update CAR T-Cell Therapy for Non-Hodgkin Lymphoma | Cancer Q&A — Discussing Common Questions Posed by Patients
Dec 11, 2025
In this insightful discussion, Dr. Jeremy S Abramson, a lymphoma specialist at Massachusetts General Hospital, and Dr. Loretta J Nastoupil from CommonSpirit Mercy Hospital explore the landscape of CAR T-cell therapy for non-Hodgkin lymphoma. They delve into patient access challenges, revealing under 20% of eligible patients reach treatment centers. The pair compare CAR T products and emphasize the importance of logistical support for patients. They also address the significance of wellness strategies and community collaboration in enhancing patient care.
AI Snips
Chapters
Transcript
Episode notes
Patient Framing: ‘Bionic’ T Cells
- A patient described CAR‑T to friends as "we made your T cells bionic" which helped others understand.
- He credited CAR‑T with saving his life and seven years of family time.
Severe Access Gap For Eligible Patients
- Fewer than 20% of Medicare-eligible relapsed large‑cell lymphoma patients who should be considered for CAR T reach a treating center.
- An even smaller fraction actually receive CAR T, highlighting major access barriers.
Logistics, Not Just Knowledge, Limit Referrals
- Awareness improved but logistics—not ignorance—now often block referrals to CAR T centers.
- Travel burden, caregiver availability, and socioeconomic strain prevent many patients from pursuing CAR T.